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Succinate dehydrogenaseMachado–Joseph disease (MJD), also known as Spinocerebellar Ataxia type 3, is an inherited dominant auto-
somal neurodegenerative disorder. An expansion of Cytosine-Adenine-Guanine (CAG) repeats in the ATXN3
gene is translated as an expanded polyglutamine domain in the disease protein, ataxin-3. Selective neurode-
generation in MJD is evident in several subcortical brain regions including the cerebellum. Mitochondrial dys-
function has been proposed as a mechanism of neurodegeneration in polyglutamine disorders. In this study,
we used different cell models and transgenic mice to assess the importance of mitochondria on cytotoxicity
observed in MJD. Transiently transfected HEK cell lines with expanded (Q84) ataxin-3 exhibited a higher sus-
ceptibility to 3-nitropropionic acid (3-NP), an irreversible inhibitor of mitochondrial complex II. Increased
susceptibility to 3-NP was also detected in stably transfected PC6-3 cells that inducibly express expanded
(Q108) ataxin-3 in a tetracycline-regulated manner. Moreover, cerebellar granule cells from MJD transgenic
mice were more sensitive to 3-NP inhibition than wild-type cerebellar neurons. PC6-3 (Q108) cells differen-
tiated into a neuronal-like phenotype with nerve growth factor (NGF) exhibited a signiﬁcant decrease in mi-
tochondrial complex II activity. Mitochondria from MJD transgenic mouse model and lymphoblast cell lines
derived from MJD patients also showed a trend toward reduced complex II activity. Our results suggest
that mitochondrial complex II activity is moderately compromised in MJD, which may designate a common
feature in polyglutamine toxicity.
© 2011 Elsevier B.V. All rights reserved.1. Introduction
Machado–Joseph disease (MJD), also known as spinocerebellar
ataxia type 3, is an inherited autosomal dominant neurodegenerative
disorder. MJD is the most common hereditary ataxia in the world, ac-
counting for 21–28% of the autosomal-dominant inherited cerebellar
ataxias [1,2]. Worldwide, it affects 1 or 2 individuals per 100000 peo-
ple, but its prevalence can increase to 1% of the population in some
regions of the globe. Clinically, MJD is characterized by progressive
gait and limb ataxia, dysarthria and a variable combination of other
symptoms including pyramidal signs, dystonia, oculomotor disorders,
faciolingual weakness, neuropathy, progressive sensory loss and
parkinsonian features [3]. The ﬁrst symptoms usually become appar-
ent in adulthood (third or fourth decade of life), although they can
manifest earlier in life in severe cases. Symptoms and neurological
deﬁcits progressively worsen over time, culminating in patients'
death 20 to 30 years later. In MJD, neurodegeneration and astrogliosis
are restricted to subcortical brain regions and are particularlyscience and Cell Biology, and
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rights reserved.prevalent in the pontine nuclei, the dentate nucleus, subthalamic
nucleus and spinal cord [3]. The mechanisms leading to neuronal dys-
function and cell death are still poorly understood.
MJD belongs to the polyglutamine (polyQ) expansion disorders, a
group of ten diseases that share the same genetic alteration, a patho-
logical increase in the number of CAG codon repeats. In MJD, the CAG
expansion is present in exon 10 of ATXN3 gene, located on chromo-
some 14 (14q32.1) [4,5]. Normal individuals have 12 to 42 CAG
repeats, but in MJD carriers, the repeat range extends from 52 to 84
[2]. The ATXN3 gene codes for the ubiquitously expressed 42 kDa pro-
tein ataxin-3, and thus, the pathological CAG-expanded gene is trans-
lated into ataxin-3 with an extended polyQ tract in its C-terminus
[6–9]. Although its full biological role remains elusive, several studies
have demonstrated that ataxin-3 binds and cleaves polyubiquitin
chains, exhibiting a deubiquitinating-like activity [10–14]. The pres-
ence of an expanded polyQ region promotes protein misfolding and
destabilization of the expanded ataxin-3 structure, leading to protein
deposition and formation of intracellular inclusions [15–18]. Intracel-
lular aggregates are found in the nuclei of neurons from degenerated
areas of MJD patient brains, as well as in nuclei and cytoplasm of cell
lines expressing expanded ataxin-3 [19–22]. Ataxin-3 localizes to the
cytoplasm and nucleus, but the presence of expanded ataxin-3 in the
nucleus seems to be important for the manifestation of disease in MJD
transgenic mice [23].
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consistent deregulation of mitochondrial activity and function in polyQ
disorders. Mitochondria from Huntington's disease (HD) patients and
transgenicmice show a decrease inmembrane potential and in the abil-
ity to retain Ca2+ [24,25]. Severe defects in mitochondrial complex II
and III activities and deﬁciency in complex IV have also been reported
to be correlated to neuronal death in HD [26–28]. PolyQ proteins also
impair mitochondrial transport in neuronal processes and induce cas-
pase activation through mitochondrial pathways [29–31]. Moreover,
polyQ disease proteins and polyQ-containing protein fragments are
able to induce mitochondrial dysfunction and mitochondrial swelling
in vitro [29]. Although much data has been gathered for other polyQ
disorders [28,32], there is a lack of information regarding altered mito-
chondrial activity inMJD and the role ofmitochondria in the progress of
this pathology. Thus, in this study we determined the susceptibility of
cells expressing expanded ataxin-3 to selective mitochondrial inhibi-
tors and assessed the activity of mitochondrial complexes inMJD trans-
genic mouse brain and human lymphoblasts. The results show a
signiﬁcant trend toward impairment in complex II in different models
of MJD and human MJD peripheral cells.
2. Materials and methods
2.1. Materials
Dulbecco's modiﬁed Eagle's medium (DMEM) and Roswell Park
Memorial Institute's medium (RPMI) were acquired from Sigma-
Aldrich Chemical Co. (St. Louis, MO, USA). Neurobasal medium and
B-27 supplement, fetal bovine serum (FBS), and horse serum were
purchased from GIBCO (Paisley, UK). Hygromycin and blasticidin
were from Invitrogen (Paisley, UK). Nerve growth factor (NGF) was
purchased from Alomone Labs (Jerusalem, Israel). Primary antibodies
against ataxin-3 1H9 (1:1000; Chemicon, USA) and microtubule asso-
ciated protein 2 (MAP-2) were obtained from Chemicon (Temecula,
CA, USA). Anti-coilin was from BD biosciences (San Jose, CA, USA)
and anti-promyelocytic leukemia protein (PML) was from Santa
Cruz Biotechology (Santa Cruz, CA, USA). Secondary antibodies for
immunocytochemistry anti-mouse Alexa-ﬂuor 594, anti-rabbit Alexa-
ﬂuor 488 and Hoechst 33342 were from Molecular Probes (Eugene,
OR, USA), while secondary antibodies for western blotting were ac-
quired from GE healthcare (Uppsala, Sweden). Superfect reagent was
purchased from Qiagen (Hilden, Germany). Unless otherwise stated,
all other reagents were from Sigma-Aldrich Chemical Co. (St. Louis,
MO, USA) and were of analytical grade.
2.2. Constructs, cell lines culture and transfections
Enhanced green ﬂuorescent protein (EGFP)-ataxin-3 (Q28) and
EGFP-ataxin-3 (Q84) plasmids encode a ﬂuorescent fusion-protein
composed of full length human ataxin-3 (MJD1a isoform)with EGFP at-
tached to its N-terminus [22]. These constructs were transfected into
HEK 293 cells with SuperFect reagent, according to manufacturer's in-
structions. HEK 293 cells were maintained in DMEM supplemented
with 10% (vol/vol) fetal bovine serum (FBS) and 1% (vol/vol) strepto-
mycin/penicillin. Stably transfected, doxycycline-inducible PC6-3 wild
type (Q28) or expanded (Q108) cell lines were kept in RPMI supple-
mented with 5% (vol/vol) FBS, 10% (vol/vol) horse serum, hygromycin,
blasticidin and 1% (vol/vol) streptomycin/penicillin. To induce neural
differentiation, PC6-3 cells were plated on poly-L-lysine-coated multi-
well plates and incubated with 100 ng/ml NGF for 7 days, in low
serum-containing medium (1% (vol/vol) FBS) to reduce cell prolifera-
tion. Expression of human ataxin-3was controlled through the addition
of doxycycline to the media. Normal and 2 MJD (JMMA and JMJW have
28/68 and 27/78 repeat alleles, respectively) lymphoblastic cell lines
were grown in RPMI supplemented with 10% (vol/vol) FBS, 250 mg/l
glucose, 10 mM HEPES, 1 mM sodium pyruvate and 1% (vol/vol)streptomycin/penicillin. All cell lines were kept in a 95% air and 5%
CO2 atmosphere at 37 °C.
2.3. Culture of cerebellar granule cells isolated from MJD transgenic mice
Cerebellar granule cells from 6 to 7 day-old MJD transgenic mouse
[33] pups or wild-type littermates were prepared according to the
protocol for the isolation of cerebellar granule cells from rat pups pre-
viously described [34], with slight modiﬁcations attending to the
different species of origin. Cells were plated on poly-L-lysine-coated
multiwell plates or glass coverslips. Cells were maintained in Neuro-
basal medium supplemented with 2% (vol/vol) B-27, 0.2 mM gluta-
mine, 100 U/ml penicillin, 0.1 mg/ml streptomycin and 24 mM KCl.
After the ﬁrst day in culture, 10 μM cytosine arabinose was added to
the media to prevent glial cell proliferation. Old mediumwas partially
removed and new medium was added to granule cells every fourth
day. Cerebellar granule cells were kept in a humidiﬁed atmosphere
of 95% air and 5% CO2, at 37 °C, and used after 7–8 days in vitro. Isolat-
ed granule cells from expanded ataxin-3 transgenic mice were as
healthy in culture as the neurons from the wild-type littermates.
2.4. Cytochemistry and immunocytochemistry
Transfected HEK 293 cells expressing EGFP-human ataxin-3 for 24
or 48 h had their media removed and were washed 2 times with phos-
phate buffered solution (PBS, in mM: 137 NaCl, 2.7 KCl, 1.4 K2HPO4, 4.3
Na2HPO4, pH 7.4). The cells then were ﬁxed with methanol:acetone
(1:1) solution for 15 min in ice. After 3washeswith PBS cells were incu-
bated with Hoechst 33342 (1 μg/μl) in PBS, for 5 min. The coverslips
were further washed with PBS and mounted in DAKO solution.
PC6-3 cells and murine cerebellar granule cells were also washed 2
times with PBS before ﬁxation with 4% (wt/vol) paraformaldehyde
(PFA) in PBS, for 15 min. Then, cells were rinsed 3 times with PBS and
opsonized with 5% (vol/vol) goat serum in PBT (phosphate-buffered
saline plus 0.1% (vol/vol) Triton X-100) for 1 h at room temperature.
Cells were stained with the primary antibodies: anti-ataxin-3 1H9
(1:1000), anti-coilin (1:350), anti-PML protein (1:350) and anti-MAP-2
(1:200) diluted in 5% (vol/vol) goat serum in PBT, for 1 h at room tem-
perature. Cells were then washed 2 times with PBS and incubated with
the secondary antibodies: anti-mouse Alexa-ﬂuor 594 (1:250) and
anti-rabbit Alexa-ﬂuor 488 (1:250) in 5% (vol/vol) goat serum in PBT
for 1 h at room temperature. The cells were stained with Hoechst
33342 (1 μg/μl) in PBS for 5 min before beingmounted in DAKO solution.
Immunoﬂuorescence was visualized with an Axioplan ﬂuores-
cence microscope (Zeiss, Thornwood, NY) using 20, 40, and 63× ob-
jectives. Images were captured digitally with a Zeiss MRM AxioCam
camera and assembled in Photoshop 7.0 (Adobe Systems, Mountain
View, CA). For each antibody, ﬂuorescence intensity was controlled
using identical capture time between genotypes, and images were
captured on a linear scale.
2.5. Cell viability assay
HEK293 cells transfected with EGFP-ataxin-3 (Q28) or (Q84) for
48 h and transgenic or wild-type cerebellar granule cells after 7 days
in culture were incubated with mitochondrial inhibitors for a 24 hour-
period. A large concentration range was tested for each of two inhibi-
tors: rotenone (10 nM–20 μM), an inhibitor of complex I, and 3-
nitropropionic acid (3-NP, 10 μM–10mM), an irreversible inhibitor of
succinate dehydrogenate. Cell viability was evaluated by following the
reduction of (3-[4-5-dimethylthiazol-2-]-2,5-diphenyltetrazolium bro-
mide (MTT). MTT (0.5 μg/ml) diluted in Krebs buffer (in mM: 120.9
NaCl, 4.8 KCl, 1.2 KH2PO4, 25.5 NaHCO3, 13 glucose, 10 HEPES, pH 7.4)
was added to the cell cultures and MTT reduction was carried on for
2 h. The resultant formazan crystals were dissolved in a HCl-
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measured at 570 nm.
2.6. Evaluation of cell membrane integrity
Extracellular medium and intracellular samples of HEK 293 cell
lines expressing EGFP-ataxin-3 for 48 h and undifferentiated PC6-3
neural cell lines expressing human ataxin-3 were collected and
stored at −80 °C. Intracellular extracts were obtained through a
double cycle of cell freezing and thawing in a HEPES-buffered solution
(10 mM HEPES+1% (vol/vol) Triton), followed by cell scraping. Intra-
cellular and extracellular samples were centrifuged at 20800×g for 10
min, at 4 °C to eliminate cell debris and the resulting supernatant was
used for the determination of lactate dehydrogenase (LDH) activity.
LDH activity was assessed spectrophotometrically by following the
conversion rate of NADH to NAD+ at 340 nm in a Perkin Elmer lambda
2 UV/VIS spectrophotometer. LDH leakagewas expressed as percentage
of the total activity (% of LDH released=extracellular LDH/extracellular
LDH+intracellular LDH) [35].
2.7. Mitochondrial fractionation
Mitochondrial crude fractions of PC6-3 and lymphoblastic cell lines
were prepared in a sucrose medium (250 mM sucrose, 20 mM HEPES,
10 mM KCl, 1.5 mM MgCl2, 1 mM EDTA, 1 mM EGTA, pH 7.4), at 4 °C.
Brieﬂy, cells were washed twice and scraped in ice-cold sucrose medi-
um, followed by homogenization in a potter (120 strokes). The homog-
enates were centrifuged in a refrigerated table-top centrifuge at
2300 rpm for 12 min at 4 °C to precipitate cell debris and nuclei. The
resulting supernatants were collected and stored at−80 °C.
Brain mitochondria were isolated from wild-type and MJD homozy-
gous transgenicmicewith 4–5 months according to amethod previously
described [36], with the slight modiﬁcations, using 0.02% (wt/vol) digi-
tonin to free mitochondria from the synaptosomal fraction. In brief,
mice were euthanized with a ketamine/xylazine solution, followed by
a brain perfusion with PBS to reduce blood contamination. The whole
brain was rapidly removed, washed, minced, and homogenized at 4 °C
in 10 ml of isolation medium (225 mM mannitol, 75 mM sucrose,
5 mMHepes, 1 mM EGTA, 1 mg/ml bovine serum albumin, pH 7.4) con-
taining 5 mg of the bacterial protease. Single brain homogenates were
brought to 30 ml and then centrifuged at 750×g (Beckman Coulter
Avanti J-26 XP1 Centrifuge) for 5 min. Mitochondria were recovered
from the supernatant by centrifugation at 12000×g for 8 min. The pellet,
including theﬂuffy synaptosomal layer, was resuspended in 10 ml of the
isolation medium containing 0.02 (wt/vol) % digitonin and centrifuged
at 12000×g for 8 min. The brown mitochondrial pellet without the
synaptosomal layer was then resuspended again in 10 ml of medium
and re-centrifuged at 12000×g for 10 min. The mitochondrial pellet
was resuspended in 300 ml of resuspension medium (225 mM manni-
tol, 75 mM sucrose, 5 mM Hepes, pH 7.4) and stored at−80 °C.
2.8. Mitochondrial respiratory chain complex activities
NADH–ubiquinone oxidoreductase assay — Complex I activity was
determined at 340 nm by following the decrease in NADH absorbance
due to ubiquinone reduction to ubiquinol [37]. Complex I activity was
expressed in nanomoles/minute/milligram protein and corresponds to
the rotenone sensitive rate. The enzyme activity was corrected for cit-
rate synthase activity.
Succinate–ubiquinone oxidoreductase assay — Complex II activi-
ty was monitored at 600 nm by following the reduction of 6,6-
dichlorophenolindophenol (DCPIP) by the ubiquinol resulting from
this reaction [38]. Complex II activity was expressed in nanomoles/
minute/milligram protein and corresponds to the thenoyltriﬂuoroa-
cetone (TTFA) sensitive rate. The enzyme activity was corrected for
citrate synthase activity.Ubiquinol–cytochrome c reductase assay— Complex III activity was
monitored at 550 nm by following the ubiquinol reduction of cyto-
chrome c. The assay was started by adding the sample to the reaction
mixture (inmM: 35 K2HPO4, pH 7.2, 1 EDTA, 5MgCl2, 1 KCN, 5 μMrote-
none) containing 15 μM cytochrome c and 15 μM ubiquinol, at 30 °C.
Complex III activity was expressed in rate constant (k) per minute per
milligram of protein and corrected for citrate synthase activity.
Cytochrome c oxidase assay — Complex IV activity was deter-
mined at 550 nm by measuring the oxidation of reduced cytochrome
c by cytochrome c oxidase [39]. Complex IV activity was expressed in
rate constant (k) per minute per milligram of protein and corrected
for citrate synthase activity.
Citrate synthase assay–Citrate synthase (CS) activity was performed
at 412 nm following the reduction of 5,5′-dithio-bis(2-nitrobenzoic
acid) in the presence of acetyl-CoA and oxaloacetate [40]. CS activity
was expressed in nanomoles/minute/milligram of protein.
2.9. SDS-PAGE and immunoblotting
Total extracts from transfected HEK 293 cells, PC6-3 cell lines or
primary cerebellar granule cells were collected and SDS-PAGE was
performed in 10% polyacrylamide gels. Next, the proteins were trans-
ferred onto polyvinylidene diﬂuoride membranes (Hybond-P, GE
healthcare), which were further blocked in a 5% (wt/vol) non-fat
milk solution for 60 min. Membranes were incubated with anti-
ataxin-3 monoclonal (1H9, 1:1000) overnight at 4 °C with agitation.
After washing, the blots were incubated with alkaline phosphatase-
conjugated anti-mouse secondary antibody and developed with en-
hanced chemiﬂuorescence. The membranes were scanned in a Biorad
VersaDoc Imaging System Model 3000.
2.10. Statistical analysis
Data were expressed as mean±SEM of the number of experi-
ments indicated in the ﬁgure legends. Comparisons among multiple
groups were analyzed with two-way analysis of variance (ANOVA)
followed by the Bonferroni post-hoc test, as indicated in the ﬁgure
legends. Comparisons between two groups/conditions were per-
formed with two-tailed unpaired Student's t-test. Signiﬁcance was
deﬁned as pb0.05.
3. Results
3.1. EGFP-ataxin-3 protein aggregation in a transient expression
cell model
We initiated our study in a transient expression cell model expres-
sing wild-type or expanded ataxin-3. HEK 293 cells were transfected
with mammalian expression vector encoding EGFP fusion protein of
wild-type (Q28) or expanded (Q84) ataxin-3 (Fig. 1A). EGFP was
located at the N-terminus of ataxin-3, near the globular Josephin do-
main containing the catalytic site. The expression of ataxin-3 fusions
was conﬁrmed by western blotting (Fig. 1B) and ﬂuorescence micros-
copy. Both expression vectors were highly expressed with similar
transfection efﬁciency (Fig. 1D). Transfected cells displayed a strong
EGFP signal 24 h after transfection (Fig. 1Ca, 1Cc). Confocal microsco-
py revealed different patterns of intracellular localization for wild-
type and expanded ataxin-3 (Fig. 1C). EGFP-ataxin-3 (Q28) was dis-
tributed homogenously throughout the cell (although more abundant
in the cytoplasm), regardless of the length of time (24 or 48 h) after
transfection or the expression levels in the cell (Figs. 1Ca, Cb). In con-
trast, EGFP-ataxin-3 (Q84) was initially diffusely distributed in the
cytoplasm and nucleus of most cells (Fig. 1Cc). However, in a small
number of cells and at a higher magniﬁcation, small sites of EGFP-
ataxin-3 (Q84) accumulation with a perinuclear distribution were
already detectable (Fig. 1Ce). At 48 h of expression, EGFP-ataxin-3
Fig. 1. EGFP-ataxin-3 Q84 fusion protein aggregates in a transiently expressed MJD cell model. HEK 293 cells were transfected with EGFP-ataxin-3 Q28 or EGFP-ataxin-3 Q84 plas-
mid constructs and their expression was carried out for 24 or 48 h. (A) Representative schemes of the wild-type (Q28) and expanded (Q84) ataxin-3 fusion protein being expressed.
(B) Total extracts prepared from HEK293 cells transfected with EGFP-ataxin-3 (Q28) or (Q84) were analyzed through western blotting for ataxin-3 to assess the expression of the
plasmid constructs. (C) Representative confocal ﬂuorescent microscopy images of HEK293 cells expressing EGFP-ataxin-3 Q28 (a, b) or EGFP-ataxin-3 Q84 (c, d, e) for 24 (a, c, e) or
48 (b, d) hours. (e) Higher magniﬁcation of HEK cells transfected with EGFP-ataxin-3 Q84 for 24 h. (D) HEK293 cells expressing EGFP-ataxin-3 Q28 or EGFP-ataxin-3 Q84 fusion
proteins were ﬁxed, nuclear stained with Hoechst 33342 and quantiﬁed through ﬂuorescent microscopy. The graph plots the percentage of cells expressing wild-type (Q28) or ex-
panded (Q84) ataxin-3 ﬂuorescent fusion proteins in three independent transfections.
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gates (Fig. 1Cd). The aggregates were not present in all transfected
cells, and were more frequent in the cells exhibiting higher levels of
ataxin-3 expression. Interestingly, in cells exhibiting protein aggre-
gates, nearly all of the intracellular pool of expanded ataxin-3 local-
ized to the aggregate.
The aggregateswere not SDS-insoluble, consistentwith earlier reports
[41,42]. The characteristic high molecular weight bands of SDS-resistant
aggregates immunopositive for ataxin-3 or retention of aggregates in
the stacking gel or in the interface between the stacking and the running
gels were not detected by western blotting (data not shown). Moreover,
longer periods of expression of EGFP-ataxin-3 (Q84) (72, 96 h) did not re-
sult in an increase in the number or size of aggregates (data not shown).
For this reason, all other experiments using this cell model were carried
out at 48 h of expression.
3.2. Inducibly expressed expanded ataxin-3 accumulates in
subnuclear compartments
To compare the formation of ataxin-3 aggregates between divid-
ing cells and neuronal-like cells in the same cellular environment,
we used stably transfected PC6-3 cell lines (a PC12 sub-clone [43]
expressing wild-type (Q28) or expanded (Q108) ataxin-3 under a
tetracycline-regulated promoter (Fig. 2). These cell lines stably over-
express human wild-type or expanded ataxin-3 when doxycycline is
administered to the culture media. Moreover, after NGF treatment,
PC6-3 cells lose their normal growth round shape to develop long
cellular processes resembling neurites, assuming a neuronal-like
morphology. After differentiation, they exhibit an excitable polarizedcell membrane sensitive to depolarization with potassium, not
responding to glutamate or acetylcholine stimuli (not shown). Low
concentrations of doxycycline (0.1 μg/ml) were efﬁcient at inducing
maximal expression of ataxin-3 in these cell lines with no further
increase in expression observed for higher dosages of the antibiotic
(Fig. 2A). There were also no signiﬁcant differences in the ataxin-3
levels produced in PC6-3 cells expressing wild-type or expanded
ataxin-3. To study the ataxin-3 distribution in cells with a neuronal-
like phenotype, PC6-3 cells were incubated with NGF for 7 days in
culture, before induction of wild-type or expanded human ataxin-3
expression for 24, 48, 72 and 96 h. Fluorescent microscopic images
of PC6-3 cells immunostained for ataxin-3 revealed that the cellular
distribution of wild-type ataxin-3 did not alter over time and no
aggregation was detected along the time of expression tested
(Fig. 2B), as previously observed in HEK293 cells (Figs. 1Ca, Cb).
However, in PC6-3 cells, wild-type ataxin-3 (Q28) had more afﬁnity
for the nuclear compartment than the EGFP-ataxin-3 Q28 fusion
protein. On the other hand, the expanded form of ataxin-3 (Q108)
exhibited a propensity to aggregate in PC6-3 cells, which was visible
already at 24 h after the induction of expression (Fig. 2B). Some
PC6-3 cells expressing expanded ataxin-3 (Q108) developed visible
ataxin-3 positive aggregates, primarily nuclear. These aggregates
were SDS-soluble, as no higher molecular weight bands or aggregates
in the stacking gel were observed on western blots (data not shown).
Interestingly, the formation of intranuclear ataxin-3 aggregates was
observed only in PC6-3 cells differentiated with NGF and therefore
committed to a neuronal intracellular environment; protein aggre-
gates were not visible in dividing cells (not shown). In cells without
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Fig. 2. Aggregates of human expanded ataxin-3 in PC6-3 ataxin-3 Q108 cells are primarily nuclear. (A) Total extracts were prepared from PC6-3 ataxin-3 Q28 cells or PC6-3 ataxin-3
Q108 cells incubated in the absence or presence of increasing concentrations (0.1, 0.3, 1, 3 and 5 μg/μl) of doxycycline for 24 h and subsequently probed for ataxin-3 on a western
blot. (B) Merged representative images of ﬂuorescent and optical differential interference contrast microscopy of PC6-3 cells incubated with doxycycline (1 μg/μl) for expression of
human ataxin-3 Q28 or human ataxin-3 Q108 during 24, 48, 72 or 96 h and immunostained for ataxin-3 (in red). (C, D) Representative images of PC6-3 ataxin-3 Q108 cells expres-
sing human expanded ataxin-3 for 48 h, which were ﬁxed and immunostained for ataxin-3 (in red) and coilin (in green) (C) or PML protein (in green) (D). Yellow shows co-
localization between proteins. Nuclei were stained with Hoechst 33342 (1 μg/ml).
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condensed almost all ataxin-3 ﬂuorescent signal into a discrete
intranuclear distribution, resembling the localization of some subnucle-
ar compartments. In order to investigate this possibility, we co-
immunostained PC6-3 cells for ataxin-3 and various signature proteins
of subnuclear structures. The aggregates co-localized with promyelocy-
tic leukemia protein (PML) andwere often juxtaposed to coilin-positive
bodies (Fig. 2C, D). Nuclear PML-enriched bodies are known to co-
localize with aggregates of polyQ proteins and the speciﬁc association
between the Cajal (coiled) bodies and expanded ataxin-3 has been pre-
viously observed [44].
3.3. Ataxin-3 aggregation in neuronal cultures from a transgenic
mouse model
We also investigated the intracellular localization of expanded
ataxin-3 in a neuronal context, using primary cultures of cerebellar
granule cells isolated from a human expanded ataxin-3 transgenic
mouse model [33]. This MJD transgenic mouse model mimics several
pathological features of MJD in humans [33]. In this model, the ex-
pression of the human expanded ataxin-3 (Q71) is under the control
of the mouse prion promoter, which drives expression of the trans-
gene throughout the brain. Intranuclear inclusions immune-positive
for ataxin-3 are detected in several subthalamic regions of the brain
and in the spinal cord of the adult mouse [33].
Western blotting of both wild-type and transgenic total brain ex-
tracts was performed to characterize expanded ataxin-3 expression
(Fig. 3B). Immunostaining for ataxin-3 was higher in the nucleus
both for cultured neurons derived from non-transgenic and transgen-
ic mice, however, there were differences in the intranuclear distribu-
tion of wild-type murine ataxin-3 and expanded human ataxin-3
(Fig. 3A). Fluorescent microscopy images revealed intranuclear foci
of expanded ataxin-3 similar to what we observed in the previouscell models. In wild-type neurons, nuclear ataxin-3 had a diffuse
and homogeneous disposition, but in the nucleus of transgenic neu-
rons, several discrete foci were easily detectable in almost all cells.
The small size and the lack of higher molecular weight bands on
western blots suggest that these ataxin-3 positive nuclear foci are
not mature, SDS-insoluble aggregates. No differences in nuclear dis-
tribution of expanded ataxin-3 were observed in cultured neurons
carrying one versus two copies of the transgene (i.e. hemizygous ver-
sus homozygous transgenic mice; data not shown). However, both
homozygous and hemizygous transgenic mice at a later age develop
intranuclear inclusions in the adult mouse brain [33].
3.4. Overexpression of expanded ataxin-3 enhances cell death upon
mitochondrial complex II inhibition
Non-transfected HEK cells and cells expressing EGFP-ataxin-3
(Q28) or EGFP-ataxin-3 (Q84) for 48 h were exposed to increasing
concentrations of inhibitors of mitochondrial respiratory chain com-
plexes I and II, rotenone and 3-NP respectively, for 24 h. Incubation
with rotenone or 3-NP induced a dose-dependent decrease in MTT re-
duction in HEK cells (Fig. 4A). Similar levels of cell death were ob-
served for ataxin-3 (Q28) and ataxin-3 (Q84) expressing HEK cell
lines subjected to rotenone treatment (Fig. 4A), suggesting that ex-
pression of expanded ataxin-3 does not affect cellular susceptibility
to inhibition of mitochondrial complex I. In contrast, a statistically
signiﬁcant difference between the survival of the two ataxin-3
expressing HEK cell lines was detected in the presence of 3-NP
(Fig. 4A). For the lower concentrations of 3-NP (100 μM and 1 mM)
tested, cells expressing EGFP-ataxin-3 (Q84) were more vulnerable
than cells expressing EGFP-ataxin-3 (Q28) cells, although statistical
signiﬁcance was only detected in the presence of 100 μM 3-NP.
Untransfected cells had a similar response to 3-NP exposure as
EGFP-ataxin-3 (Q28) cell line, indicating that the differences in cell
Fig. 3. Aggregation in the human expanded ataxin-3 transgenic mouse. (A) Cerebellar granule cells were isolated from 7 days wild-type (a, b, c) or transgenic (d, e, f) pups and kept
in culture for 7 days. Cells were stained for MAP-2 (a, c, d, f— in green) and ataxin-3 (b, c, e, f— in red) and visualized through ﬂuorescence microscopy. (g) Higher magniﬁcation of
transgenic cerebellar granule cell immunostained for MAP-2 (in green) and ataxin-3 (in red). (B) Western blotting for ataxin-3 was performed in total brain extracts of wild-type
(wt/wt), or transgenic (one copy (wt/mjd) or two copies (mjd/mjd) of the transgene) 4 month old mice to evaluate the expression of the transgene and the aggregation of human
expanded ataxin-3.
144 M.N. Laço et al. / Biochimica et Biophysica Acta 1822 (2012) 139–149viability observed at low 3-NP concentrations were not due to trans-
fection procedures, nor to the overexpression of ataxin-3 per se
(Fig. 4A). Antimycin A, an inhibitor of complex III, was also tested in
the HEK cell lines, but there were no differences in cell survival be-
tween wild-type and expanded ataxin-3 expressing cells (Fig. S1 —
Supplementary data).
Cerebellar granule neurons from MJD transgenic or non-transgenic
mice were also exposed to inhibitors of mitochondrial complexes I
and II, rotenone and 3-NP respectively, for 24 h. In comparison to HEK
293 cells, the cerebellar granule neurons were more susceptible to
rotenone or 3-NP (Fig. 4). At 1 mM 3-NP, around 25% of the cerebellar
granule cells survived, in contrast to 75% survival of HEK cells. Non-
transgenic andMJD neurons responded similarly to rotenone inhibition
(Fig. 4B). On the contrary, transgenic cerebellar granule cells exhibited a
higher susceptibility for 30 μM3-NP, when compared towild-type neu-
rons (Fig. 4B).
3.5. Transient expression of expanded ataxin-3 promotes loss of
membrane integrity
3-NP-induced cell deathwas also analyzed by following LDH leakage
in transfected HEK cells. Increasing 3-NP dosage induced higher levels
of extracellular LDH. Statistically signiﬁcant differences between these
two transfected cell lines were observed for low 3-NP concentrations
(Fig. 5A). At 100 μM3-NP, the EGFP-ataxin-3 (Q84) line showed higher
extracellular LDH levels than EGFP-ataxin-3 (Q28) expressing cells,
supporting the lower cell viability at this concentration, as observed
before. Interestingly, the EGFP-ataxin-3 (Q84) cell line exhibited a ten-
dency toward a higher basal LDH release, which was statistically differ-
ent from the EGFP-ataxin-3 (Q28) expressing cells (Fig. 5A), suggesting
that expression of expanded ataxin-3 might decrease membrane integ-
rity. Adenosine triphosphate (ATP) levels, adenosine diphosphate
(ADP) levels and caspase-3-like activity were also measured in HEKcells expressing ataxin-3 under the same experimental conditions
described above. Neither the incubation with 3-NP nor the expression
of expanded ataxin-3 altered any of these parameters in these cells
(data not shown). The increased loss of membrane integrity (LDH re-
lease) and the absence of activated caspase-3 in western blotting and
ﬂuorimetric assays suggested that EGFP-ataxin-3 cell lines were most
certainly dying through necrosis or a caspase-3 independent pathway.
We also examined the susceptibility to complex II inhibition in
NGF-differentiated PC6-3 cells expressing wild-type (Q28) or ex-
panded (Q108) ataxin-3. Fig. 5B shows that concentrations of 3-NP
from 10 μM to 3 mM do not change signiﬁcantly the release of LDH.
However, there was a strong increase in the LDH release for both
cell lines in the presence of 10 mM 3-NP (Fig. 5B). The expanded
ataxin-3 PC6-3 cells displayed statistically signiﬁcant higher levels
of extracellular LDH for this concentration, compared to wild-type
ataxin-3 (Q28).
3.6. Expression of expanded ataxin-3 affects mitochondrial
complex II activity
The increased susceptibility to 3-NP observed in different MJD cell
models led us to hypothesize that expanded ataxin-3 overexpression
could affect the mitochondria at the level of mitochondrial complex II.
Therefore, we next determined the activities of all themitochondrial re-
spiratory complexes in several MJDmodels with the purpose of detect-
ing any other effects expanded ataxin-3 might have on mitochondrial
electron transport chain. To accomplish this, we collectedmitochondri-
al crude samples from undifferentiated and NGF-differentiated PC6-3
cell lines expressing human ataxin-3, wild-type and MJD transgenic
adult mouse brains, and three human lymphoblastic cell lines. Mito-
chondria from whole mouse brain were obtained from non-transgenic
or homozygous transgenic mice at 4–5 months of age. At this age, ho-
mozygous MJD mice manifest clear symptoms of abnormal phenotype
Fig. 4. Overexpression of expanded ataxin-3 (Q84) increases cell susceptibility to low concentrations of 3-nitropropionic acid (3-NP). HEK 293 cells transfected with EGFP-ataxin-3
(Q28) or (Q84) (A) or cerebellar granule cells from wild-type or transgenic mice pups (B) were incubated with rotenone (10 nM–20 μM) or 3-NP (10 μM–10 mM), for 24 h. After
this incubation period, cell viability was assessed by MTT (0.5 μg/ml) reduction. Graphs summarize the mean±SEM of the percentage of control for each cell type of 4–8 indepen-
dent experiments, run in duplicates. Statistical analysis: ** pb0.01, compared to HEK 293 EGFP-ataxin-3 Q28 treated with 100 μM 3-NP, two-way ANOVA followed by Bonferroni
multiple comparison test; t pb0.05, compared to wild-type cerebellar granule cells treated with 30 μM 3-NP (Student's t-test).
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established after immortalization of lymphoblasts collected from two
MJD patients and one healthy individual [6], with the two MJD
lymphoblastic cell lines containing 27/78 (JMJW) and 28/68 (JMMA)
CAG repeat alleles.Fig. 5. Expanded ataxin-3 induces higher levels of cell death. HEK 293 cells expressing EG
(Q108) human ataxin-3 (B) were exposed to increasing concentrations of 3-NP (100 μM a
and the extracellular media of every sample were collected and analyzed for LDH activity
extracellular LDH activity of the total LDH activity, for each sample. 4–15 independent ex
EGFP-ataxin-3 Q28 (Student's t-test); * pb0.05 compared to HEK 293 EGFP-ataxin-3 Q28 tre
test. (B) *** pb0.001 compared to PC6-3 Ataxin-3 Q28 treated with 10 mM 3-NP, two-wayMeasurement of the activity of individual mitochondrial complexes
revealed a common trend throughout the three MJD models tested
(Fig. 6). In all models, no alterations were detected in the activities of
complexes I, III and IV in the presence of expanded ataxin-3. Neverthe-
less, strong tendencies, and in some cases signiﬁcant differences, wereFP-ataxin-3 Q28 or Q84 (A) and PC6-3 cells expressing wild-type (Q28) or expanded
nd 1 mM for HEK cells (A); 10 μM–10 mM for PC6-3 cells (B)), for 24 h. Total extracts
to evaluate the degree of cell death. Graphs plot the mean±SEM of the percentage of
periments were conducted. Statistical analysis: (A) tt pb0.01 compared to HEK 293
ated with 100 μM 3-NP, two-way ANOVA followed by Bonferroni multiple comparison
ANOVA followed by Bonferroni multiple comparison test.
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ly signiﬁcant differenceswere observed inNGF-differentiated PC6-3 cell
lines expressing expanded versus wild-type human ataxin-3 (Fig. 6A).
PC6-3 ataxin-3 (Q108) cells exhibited an approximately 25% reduction
in complex II activity, compared to PC6-3 ataxin-3 (Q28). A decrease in
complex II activity was also determined for the MJD human lympho-
blastic cell lines, although statistically signiﬁcancewas not achieved. Ac-
cordingly, the protein levels of complex II subunits (ShdA and ShdB)
were not altered in mitochondrial extracts of MJD lymphoblastic cell
lines (Fig. S2 — Supplementary data).
4. Discussion
Human ataxin-3 has been shown to have an inherent capacity to
self-aggregate, even the wild-type variant [45]. The presence of a
pathological polyQ tract in the ataxin-3, however, introduces an addi-
tional step in the aggregation process, resulting in the formation of
highly stable and SDS-insoluble aggregates [41]. The presence of pro-
tein aggregates containing expanded ataxin-3 and other proteins in
speciﬁc areas of the brain of MJD patients is a pathological hallmark
of this neurological disease [19,46,47]. In agreement with this,
ataxin-3 protein aggregation was observed in the cell and animal
models used in this study and occurred selectively in the expanded
ataxin-3-expressing models. Analysis of mitochondrial susceptibility
in ataxin-3 expressing models revealed that the mitochondrial inhib-
itor producing the strongest response throughout the different
models was 3-NP, an irreversible complex II inhibitor. Indeed, most
of the MJD cell models showed a tendency toward increased suscep-
tibility to 3-NP treatment and decreased activity of complex II.
Higher levels of protein and the expression of a more aggregation-
proned isoform (MJD1a) of expanded ataxin-3 may account for the
larger aggregates observed in HEK EGFP-ataxin-3 (Q84) cells. Although
in some in vitro studieswild-type ataxin-3 has been shown to aggregate
[41,45], in cells we only observed aggregation of expanded ataxin-3.
Aggregation of expanded EGFP-ataxin-3 (Q84) in HEK 293 cell
lines was associated with deleterious effects, increasing the suscepti-
bility to mitochondrial complex II inhibitor (3-NP) treatment. Indeed,
expression of expanded ataxin-3 alone was sufﬁcient to increase cell
death in this model. Aggregation of expanded ataxin-3 in PC6-3
ataxin-3 (Q108) cells decreased cell survival only in the presence of
high 3-NP concentrations, compared to HEK EGFP-ataxin-3 (Q84)
cells or MJD cerebellar granule cells, which may account for a lower
expression of the transgene in these cells. The aggregates in PC6-3
cells and transgenic cerebellar granule cells are discrete nuclear struc-
tures and smaller than the bulky clumps observed in HEK 293 cells.
Steric interference caused by the larger aggregates in HEK 293 cells
over intracellular movement of proteins and organelles, might
contribute for the increased cytotoxicity in these cells. The nuclear
localization of aggregates in PC6-3 ataxin-3 (Q108) cells was not ran-
dom. They were intimately associated with PML bodies and closely
juxtaposed to coiled or Cajal bodies. PML bodies have been described
as sites of protein degradation in the nucleus, while Cajal bodies are
part of a subnuclear organelle implicated in RNA splicing [48–50].
The close location of expanded ataxin-3 aggregates to nuclear sites
of protein degradation may represent a cellular effort to degrade the
accumulated protein. Additionally, these speciﬁc nuclear sites may
gather speciﬁc proteins or factors that trigger the seeding stages of
expanded ataxin-3 deposition.
Although expanded ataxin-3 is expressed throughout the body,
only neurons of some subcortical regions of the brain degenerate in
MJD patients. Interestingly, the cells from these regions also represent
some of the main sites of ataxin-3 aggregation [46]. In accordance, the
formation of aggregates selectively occurs in PC6-3 (Q108) cells com-
mitted to a neuronal phenotype (i.e., upon differentiation with NGF)
and is associated with increased susceptibility to high concentrations
of the mitochondrial complex II inhibitor, 3-NP.Accumulation of human expanded ataxin-3 in discrete subnuclear
sites was also observed in neuronal cultures derived from MJD trans-
genic mice. Even though the cerebellar granule cells were collected
from 7 day-old mouse pups, nuclear foci of accumulated ataxin-3
were already detectable, suggesting that at least the subnuclear local-
ization of expanded ataxin-3, may start early in development, well
before the ﬁrst signs of neuropathology. These early stages of expand-
ed ataxin-3 accumulation were accompanied by a mild mitochondrial
susceptibility of cerebellar MJD neurons. Expanded ataxin-3 inclu-
sions in this mouse model have only been reported in adulthood,
starting at 2.5 months of age [33]. Therefore, the expanded ataxin-3
nuclear foci detected in 7 day-old transgenic neurons may represent
the initial stages of ataxin-3 accumulation not yet capable of exerting
a full toxic effect. Although the discussion regarding the protective
versus pathological role of polyQ aggregates is not fully resolved
[51], in our experimental models, aggregates of expanded ataxin-3,
which may be dimers, oligomers, or higher order aggregates, were
associated with increased cell death.
Activation of mitochondrial apoptotic pathways and reduction in
antioxidant enzymes activity followed by increased mitochondrial
DNA damage have been reported for cellular models of MJD, estab-
lishing a mitochondrial role in MJD pathology [42,52,53]. We have
not observed apoptotic events or energy deﬁcits upon expression of
expanded ataxin-3 in HEK293 cells. However, expanded ataxin-3
may exert its pathological effects by interfering and disrupting addi-
tional biochemical pathways. Notably, mitochondrial complex II or
succinate dehydrogenase is a biochemical converging point between
the mitochondrial electron chain and the citric acid or Krebs cycle.
Interestingly, we observed that complex II was the only mitochondri-
al complex to exhibit a consistent tendency toward decreased activity
in the presence of expanded ataxin-3, particularly in differentiated
PC6-3 cells expressing ataxin-3 (Q108) and in lymphoblastic cell
lines derived from MJD patients. Complex II activity in brain mito-
chondria from MJD transgenic mice showed to be more resilient to
human expanded ataxin-3 toxicity. The capacity to sustain a satisfac-
tory complex II activity may be associated to an absence of major
neurodegeneration, previously described in this MJD transgenic
model [33]. On the other hand, the mild decrease in complex II activ-
ity in dividing, peripheral cells such as MJD lymphoblastic cell lines is
a rather interesting result. Indeed, more studies need to be carried out
to verify this direct relationship between expression of expanded
ataxin-3 and the drop in complex II activity. Inhibition of complex II
was previously linked to production of reactive oxygen species
(ROS) [54,55]. Thus, increased oxidative stress in cells expressing
expanded ataxin-3 would explain the increased susceptibility to
ROS induced by the extra complex II inhibition provided by 3-NP
treatment. Nevertheless, complex I and complex III inhibitions did
not increase cell susceptibility of expanded ataxin-3 expressing
cells, suggesting the possibility that oxidative stress should not be
the only mechanism underlying ataxin-3 toxicity. Although complex
II does not contribute to the mitochondrial proton gradient, disrup-
tion of normal mitochondrial calcium handling might be another
mechanism involved in ataxin-3 pathology. It is worth noting that a
signiﬁcant decrease in complex II activity was observed in a cell
model committed to a neuronal phenotype, the NGF-treated PC6-3
ataxin-3 (Q108) cells.
These cells show aggregates of expanded ataxin-3 occurring pri-
marily in the nucleus, despite the low levels of expanded ataxin-3
expression. Although, complex II is the only mitochondrial complex
of the respiratory chain that is exclusively nuclear-encoded and
expanded ataxin-3 has been reported to interfere with gene expres-
sion in the nucleus [17], we have not found alterations in protein
levels of complex II subunits in MJD lymphoblasts (Fig. S2 — Supple-
mentary data). Nevertheless, the activity of complex II is not solely
determined by changes in the expression of its subunits. Alterations
in regulatory proteins involved in phosphorylation and acetylation
Fig. 6. Expanded ataxin-3 expression impairs mitochondrial complex II activity. The activities of complexes I, II, III and IV of the mitochondrial respiratory chain were determined spectrophotometrically in (A) mitochondrial extracts from
undifferentiated and NGF-differentiated PC6-3 ataxin-3 Q28 and Q108 cell lines, (B) isolated brain mitochondria of 4–5 months wild-type or MJD homozygous transgenic mice, and (C) human lymphoblastic cell lines derived from MJD
patients (JMMA, JMJW) or control individuals. Graph shows the mean±SEM of 4–9 independent measurements of the mitochondrial complexes activities. The activities of mitochondrial complexes were normalized for citrate synthase
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ity of chaperones responsible for complex II assembly could also in-
terfere with its activity, without altering the protein levels. One or
more of these phenomena may contribute to mitochondrial dysfunc-
tion in MJD.
Ataxin-3 is a deubiquitinating enzyme that has been implicated in
the ubiquitin–proteasome pathway and in cellular protein quality con-
trol. Recent studies have described a crosstalk between the mitochon-
dria and the proteasome [57]. Expression of expanded ataxin-3 may
impair the ubiquitin–proteasome system or disrupt the crosstalk be-
tween the proteasome and mitochondria. Similarly to what was found
upon expression of mutant huntingtin [58], macroautophagy malfunc-
tion may also occur in the context of expanded ataxin-3 expression
due to a failure on the engulfment of cytosolic components in autopha-
gosomes, precluding an adequate elimination of aggregated proteins
and/or dysfunctional mitochondria. Indeed, impaired protein degrada-
tion pathways may delay protein turnover, promoting the accumula-
tion of altered mitochondrial complexes with reduced activity. An
impairment of mitochondrial complex II in MJD cell and animal models
is particularly intriguing considering that selective vulnerability to com-
plex II inhibitors and defects in complex II activity have been reported
for other polyQ diseases, especially HD [26,59]. Mitochondrial complex
II impairment might be central to some of the biochemical changes
elicited by various polyQ expanded proteins,making thismitochondrial
complex an important target in polyQ toxicity.
Supplementary materials related to this article can be found on-
line at doi:10.1016/j.bbadis.2011.10.010.Acknowledgements
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